Nanovector was founded in 2001 and is one of the companies that first began working in the nanomedicine field in Italy, having a specific focus on developing its technical platform for drug-delivery applications. Proprietary lipid nanocarriers, microemulsions and Solid Lipid Nanoparticles have been tested over recent years, delivering different drugs by different administration routes: in this profile, a short overview of our main results will be given. The delivery system platform has shown and confirmed promising characteristics. Focusing on solid lipid nanoparticles, a leading possibility as a carrier for hydrophobic and hydrophilic drugs, we have tested four administration routes (intravenous, oral/duodenal, eye topical and transdermal), their rapid internalization into cells, their in vivo targeting to areas not usually reached (brain and eye posterior globe) and their ability to cross the intestinal mucosa, thus enabling administration of drugs from intravenous to oral. Nanovector aims to exploit the proprietary technical platform to develop therapeutics in areas with strong unmet medical needs and promising market opportunities.